ADAM17 is the protein that’s not content with just one stage name. Also known as TACE (TNF-α Converting Enzyme), this molecular diva is the ultimate multi-tasker of the cellular world. Picture ADAM17 as the gossip columnist of the cell, always ready to spread the latest news. But instead of whispers and rumors, it’s spreading cellular signals faster than you can say “reproductive revolution!”

In the reproductive realm, ADAM17 is like that friend who’s always stirring the pot. It’s involved in everything from sperm maturation to egg development, and it doesn’t stop there. This protein is so extra, it even plays a role in placental development. Talk about being involved from conception to delivery.

But here’s where it gets juicy. ADAM17 isn’t just a reproductive specialist; it’s a jack-of-all-trades. It’s involved in immune responses, heart development, and even cancer. It’s like the Kevin Bacon of proteins – somehow connected to everything. Now, you might be wondering, “What’s this got to do with snake venom?” Well, imagine ADAM17 as the Hollywood star who got its start in B-grade horror movies (aka snake venom proteins) but has now made it to the big leagues of cellular signaling.

Scientists are still trying to untangle all of ADAM17’s roles, but they know it’s crucial for life. Mice without ADAM17 don’t even make it to birth, that’s how important this drama queen is. In the cellular soap opera, ADAM17 isn’t just a supporting actor; it’s the star, the director, and probably writing half the script too. It’s cutting proteins left and right, releasing signals, and generally making sure everyone in the cell knows what’s going on. So, the next time you’re thinking about the miracle of life, remember ADAM17; the protein that proves sometimes, to make life happen, you need a little drama.

New Information – ADAM17: The Cancer Connection

ADAM17, also known as TACE (tumor necrosis factor-α-converting enzyme), has emerged as a key player in cancer development and progression. Recent research published in May 2024 has shed new light on ADAM17’s role and potential as a therapeutic target:

–ADAM17 controls the rapid release of at least 80 signaling molecules, including tumor necrosis factor and epidermal growth factor, which are crucial for cell communication and cancer progression.

–The protein iRhom2 acts as a gatekeeper to the ADAM17 lifecycle, interacting with key regions that control its activity.

–Scientists have revealed structures of the human ADAM17/iRhom2 complex in both active and inactive states, providing potential avenues for drug design.

–Targeting the interaction between ADAM17 and iRhom2 could be a novel approach to reduce ADAM17 activity and potentially combat cancer.

–ADAM17 inhibition in CD8+ T cells has shown promise in improving the efficacy of chimeric antigen receptor (CAR) T cells in solid tumors, offering a potential new strategy for cancer immunotherapy.